These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35020530)

  • 21. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
    Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Morris PS
    BMC Pediatr; 2021 Mar; 21(1):117. PubMed ID: 33685411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.
    Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS
    Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Skull SA; Oguoma VM; Chatfield M; Lehmann D; Binks MJ; Licciardi PV; Andrews R; Snelling T; Krause V; Carapetis J; Chang AB; Morris PS
    Int J Pediatr Otorhinolaryngol; 2023 Dec; 175():111776. PubMed ID: 37951020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
    Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
    PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules.
    Leach AJ; Wigger C; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
    BMC Pediatr; 2014 Aug; 14():200. PubMed ID: 25109288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panel 6: Vaccines.
    Pettigrew MM; Alderson MR; Bakaletz LO; Barenkamp SJ; Hakansson AP; Mason KM; Nokso-Koivisto J; Patel J; Pelton SI; Murphy TF
    Otolaryngol Head Neck Surg; 2017 Apr; 156(4_suppl):S76-S87. PubMed ID: 28372533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme.
    Aljunid S; Maimaiti N; Ahmed Z; Muhammad Nur A; Md Isa Z; Azmi S; Sulong S
    Value Health Reg Issues; 2014 May; 3():146-155. PubMed ID: 29702920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media.
    Dagan R; Van Der Beek BA; Ben-Shimol S; Pilishvili T; Givon-Lavi N
    Clin Infect Dis; 2021 Aug; 73(4):650-658. PubMed ID: 33507250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
    Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.
    Plosker GL
    Paediatr Drugs; 2014 Oct; 16(5):425-44. PubMed ID: 25192686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
    Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
    Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
    Leach AJ; Wigger C; Hare K; Hampton V; Beissbarth J; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
    BMC Pediatr; 2015 Oct; 15():162. PubMed ID: 26482232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children.
    Shiragami M; Mizukami A; Leeuwenkamp O; Mrkvan T; Delgleize E; Kurono Y; Iwata S
    Infect Dis Ther; 2014 Dec; 4(1):93-112. PubMed ID: 25527448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States.
    Zhou X; de Luise C; Gaffney M; Burt CW; Scott DA; Gatto N; Center KJ
    Int J Pediatr Otorhinolaryngol; 2019 Apr; 119():96-102. PubMed ID: 30690309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
    Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
    BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.